441 related articles for article (PubMed ID: 19929170)
1. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
2. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
3. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
[TBL] [Abstract][Full Text] [Related]
4. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
5. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
6. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of the host restriction factor tetherin in viral immune sensing.
Hotter D; Sauter D; Kirchhoff F
J Mol Biol; 2013 Dec; 425(24):4956-64. PubMed ID: 24075872
[TBL] [Abstract][Full Text] [Related]
8. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
11. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
13. BST-2/tetherin: a new component of the innate immune response to enveloped viruses.
Evans DT; Serra-Moreno R; Singh RK; Guatelli JC
Trends Microbiol; 2010 Sep; 18(9):388-96. PubMed ID: 20688520
[TBL] [Abstract][Full Text] [Related]
14. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
15. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
17. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
18. BST-2 mediated restriction of simian-human immunodeficiency virus.
Ruiz A; Lau D; Mitchell RS; Hill MS; Schmitt K; Guatelli JC; Stephens EB
Virology; 2010 Oct; 406(2):312-21. PubMed ID: 20708210
[TBL] [Abstract][Full Text] [Related]
19. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
[TBL] [Abstract][Full Text] [Related]
20. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.
Pardieu C; Vigan R; Wilson SJ; Calvi A; Zang T; Bieniasz P; Kellam P; Towers GJ; Neil SJ
PLoS Pathog; 2010 Apr; 6(4):e1000843. PubMed ID: 20419159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
